Screener
Veradermics MANE Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Veradermics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 5:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001827635-26-000019
| (in thousands) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Initial public offering, net of issuance costs paid | 269,102 | — |
| Exercise of stock options | 11 | — |
| Net cash provided by financing activities | 269,113 | 8,423 |
| Net increase (decrease) in cash and cash equivalents | 146,646 | (20,644) |
| Cash and cash equivalents—beginning of period | 21,766 | 53,084 |
| Cash and cash equivalents—end of period | $168,412 | $32,440 |
| Supplemental schedule of noncash activities: | ||
| Unrealized loss on marketable securities | $(584) | — |
Item 1. Condensed Consolidated Financial Statements (
FAQ
- What is Veradermics's net change in cash?
- Veradermics (MANE) reported net change in cash of $146.65M in Q1 2026.
- How has Veradermics's net change in cash changed year-over-year?
- Veradermics's net change in cash increased by 810.4% year-over-year, from -$20.64M to $146.65M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Veradermics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude